Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 6
1995 9
1996 7
1997 11
1998 22
1999 65
2000 76
2001 61
2002 66
2003 54
2004 37
2005 37
2006 64
2007 56
2008 47
2009 97
2010 128
2011 124
2012 101
2013 120
2014 120
2015 91
2016 81
2017 61
2018 71
2019 53
2020 67
2021 55
2022 47
2023 47
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

1,735 results

Results by year

Filters applied: . Clear all
Page 1
Antiviral therapies for influenza.
Chan KKP, Hui DSC. Chan KKP, et al. Curr Opin Infect Dis. 2023 Apr 1;36(2):124-131. doi: 10.1097/QCO.0000000000000910. Epub 2023 Jan 30. Curr Opin Infect Dis. 2023. PMID: 36752709 Review.
We reviewed the four marketed neuraminidase inhibitors (NAI e.g., oseltamivir, zanamivir, peramivir, laninamivir) and the only endonuclease inhibitor (baloxavir) on their clinical therapeutic effects and the ability of viral suppression in various groups of patients of dif …
We reviewed the four marketed neuraminidase inhibitors (NAI e.g., oseltamivir, zanamivir, peramivir, laninamivir) and the only endonu …
Neuraminidase inhibitors for preventing and treating influenza in adults and children.
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ. Jefferson T, et al. Cochrane Database Syst Rev. 2014 Apr 10;2014(4):CD008965. doi: 10.1002/14651858.CD008965.pub4. Cochrane Database Syst Rev. 2014. PMID: 24718923 Free PMC article. Review.
We included 53 trials in Stage 1 (a judgement of appropriate study design) and 46 in Stage 2 (formal analysis), including 20 oseltamivir (9623 participants) and 26 zanamivir trials (14,628 participants). Inadequate reporting put most of the zanamivir studies and hal …
We included 53 trials in Stage 1 (a judgement of appropriate study design) and 46 in Stage 2 (formal analysis), including 20 oseltamivir (96 …
An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections.
Liu X, Balligand T, Carpenet C, Ploegh HL. Liu X, et al. Sci Immunol. 2023 Jun 23;8(84):eadg9459. doi: 10.1126/sciimmunol.adg9459. Epub 2023 Jun 23. Sci Immunol. 2023. PMID: 37352373
This adduct was designed to achieve half-life extension of zanamivir through complex formation with the much-larger immunoglobulins in the circulation. The zanamivir moiety targets the adduct to virus-infected cells, whereas the anti-kappa component simultaneously d …
This adduct was designed to achieve half-life extension of zanamivir through complex formation with the much-larger immunoglobulins i …
Antivirals Targeting the Neuraminidase.
Gubareva L, Mohan T. Gubareva L, et al. Cold Spring Harb Perspect Med. 2022 Jan 4;12(1):a038455. doi: 10.1101/cshperspect.a038455. Cold Spring Harb Perspect Med. 2022. PMID: 32152244 Free PMC article. Review.
Four NA inhibitors are now licensed in various parts of the world (zanamivir, oseltamivir, peramivir, and laninamivir) to treat influenza A and B infections. ...
Four NA inhibitors are now licensed in various parts of the world (zanamivir, oseltamivir, peramivir, and laninamivir) to treat influ …
Antiviral Treatments for Influenza.
Palomba E, Castelli V, Renisi G, Bandera A, Lombardi A, Gori A. Palomba E, et al. Semin Respir Crit Care Med. 2021 Dec;42(6):859-872. doi: 10.1055/s-0041-1733830. Epub 2021 Dec 16. Semin Respir Crit Care Med. 2021. PMID: 34918326 Review.
Efficacy and safety profile of neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) and recently approved cap-dependent endonuclease inhibitor baloxavir marboxil are reported in literature, but still little information is available about special popula …
Efficacy and safety profile of neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) and recently approved cap-de …
Neuraminidase inhibition improves endothelial function in diabetic mice.
Foote CA, Ramirez-Perez FI, Smith JA, Ghiarone T, Morales-Quinones M, McMillan NJ, Augenreich MA, Power G, Burr K, Aroor AR, Bender SB, Manrique-Acevedo C, Padilla J, Martinez-Lemus LA. Foote CA, et al. Am J Physiol Heart Circ Physiol. 2023 Dec 1;325(6):H1337-H1353. doi: 10.1152/ajpheart.00337.2023. Epub 2023 Oct 6. Am J Physiol Heart Circ Physiol. 2023. PMID: 37801046
In humans, a single-arm trial (NCT04867707) of zanamivir inhalation did not reduce plasma neuraminidase activity, improved glycocalyx length, or enhanced FMD. Although zanamivir plasma concentrations in mice reached 225.8 22.0 ng/mL, in humans were only 40.0 7.2 ng/ …
In humans, a single-arm trial (NCT04867707) of zanamivir inhalation did not reduce plasma neuraminidase activity, improved glycocalyx …
Treatment of influenza with neuraminidase inhibitors.
Beard KR, Brendish NJ, Clark TW. Beard KR, et al. Curr Opin Infect Dis. 2018 Dec;31(6):514-519. doi: 10.1097/QCO.0000000000000496. Curr Opin Infect Dis. 2018. PMID: 30320639 Review.
Influenza.
Jefferson T. Jefferson T. BMJ Clin Evid. 2009 Mar 12;2009:0911. BMJ Clin Evid. 2009. PMID: 19445759 Free PMC article. Review.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: vaccines, amantadine, oseltamivir, zanamivir, rimantadine....
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: vacci …
Neuraminidase inhibitors for influenza.
Krumholz HM. Krumholz HM. BMJ. 2014 Apr 9;348:g2548. doi: 10.1136/bmj.g2548. BMJ. 2014. PMID: 24811413 No abstract available.
Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses.
Doll MK, Winters N, Boikos C, Kraicer-Melamed H, Gore G, Quach C. Doll MK, et al. J Antimicrob Chemother. 2017 Nov 1;72(11):2990-3007. doi: 10.1093/jac/dkx271. J Antimicrob Chemother. 2017. PMID: 28961794 Review.
Oseltamivir versus no treatment was associated with a decrease in hospitalization and pneumonia risk/odds in 2/4 SR/MAs. Oseltamivir (n = 4) and zanamivir (n = 3) were consistently associated with a 0.5 - 1 day decrease in symptom duration. Oseltamivir (n = 4) or zanami …
Oseltamivir versus no treatment was associated with a decrease in hospitalization and pneumonia risk/odds in 2/4 SR/MAs. Oseltamivir (n = 4) …
1,735 results